KOSDAQBiotech & Pharma065170

BL Pharmtech

₩1,410▲ 1.88%2026-11-18 close
Market Cap
₩39.4B
Turnover
₩400M
Volume
320K
Shares out.
27.9M
PER
—
PBR
5.4×
EPS
-₩543
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Quarterly Profit Amid Shrinking Sales; Licensing Is the Swing Factor

BL Pharmtech posted operating profit in Q1 and Q3 2026 even as sales have fallen for three straight years, but a controlling-shareholder net loss of KRW 15.2 billion over the last four quarters leaves licensing of its molecular glue oncology pipeline as the key swing factor.

  1. 1

    Sales fell to KRW 6.51 billion in 2025 from KRW 80.6 billion in 2022, and health functional foods still make up most of revenue.

  2. 2

    Operating profit was KRW 49.06 million in Q1 2026 and KRW 32.45 million in Q3 2026, while Q2 2026 posted an operating loss of KRW 1.34 billion.

  3. 3

    The controlling-shareholder net loss totaled KRW 15.2 billion over the last four quarters, diverging from the operating profit recorded in Q1 and Q3 2026.

  4. 4

    The molecular glue pipeline, led by ML301, has not yet entered clinical trials, and the terms and timing of any licensing deal have not been disclosed.

  5. 5

    PER cannot be calculated given recent net losses, PBR sits in a range carrying a large premium to net asset value, and total equity was KRW 7.93 billion at end-2025 with a debt ratio of 129.5%.

02

Business structure

BL Pharmtech was founded in 1995 and listed on KOSDAQ in 2002, and since acquiring BL Science in 2020 it operates three divisions: in-vitro diagnostic devices, household and health products, and anticancer drug development.

Revenue is centered on distribution of health functional foods, which accounted for 65.7 percent of sales in 2025, while food products, diagnostic kits, and women's sanitary products made up the remaining 34.3 percent. Key products include the Gainpad women's health diagnostic kit and the Dr.

Feets product, which is built on a GLP-1 activation mechanism, and the company said in September 2026 that a GLP-1 weight management probiotic scheduled for launch in the second half would be included in its global distribution lineup.

In overseas markets, the company signed a distribution agreement with France's E.Leclerc and in September 2026 entered a strategic partnership with a global social commerce company to sell through YouTube and TikTok.

The core of the drug development business is a molecular glue based anticancer pipeline developed by subsidiary BL Melanics.

Lead candidate ML301 targets refractory solid tumors that depend on the alternative lengthening of telomeres (ALT) mechanism, and the company plans to broaden its platform through ML303, an ADC and DAC conjugation strategy, and ML304, a central nervous system strategy using a blood-brain barrier shuttle.

However, ML301 is still at an early stage that has not entered clinical trials, and current revenue rests on health functional food distribution. The customer base is shifting from a domestic focus toward overseas social media distribution networks.

Large domestic and international biopharma companies have been named as potential licensing partners, but the terms and timing of any deal have not been disclosed.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩900M-₩500M−55.4%
2025Q4₩800M-₩1.1B−141.0%
2026Q1₩1.5B₩49,061,6553.2%
2026Q2—-₩1.3B—
2026Q3₩1.1B₩32,450,6682.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩80.6B-₩2.8B-₩13.9B−3.4%−41.1%152.4%
2023₩24.5B-₩6.8B-₩100M−27.7%−0.5%40.9%
2024₩8.8B-₩3.2B-₩5.7B−36.5%−23.5%50.2%
2025₩6.5B-₩2.8B-₩16.8B−43.4%−212.5%129.5%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual results show a structure of continuing sales declines alongside operating losses that have persisted for four consecutive years.

Sales fell from KRW 80.6 billion in 2022 to KRW 24.5 billion in 2023 (down 69.6 percent year on year), KRW 8.81 billion in 2024 (down 64.1 percent), and KRW 6.51 billion in 2025 (down 26.1 percent), a three-year decline from 2023 through 2025; 2022 was the largest year and 2025 the smallest in the 2022 to 2025 period.

Operating loss widened from KRW 2.78 billion in 2022 to KRW 6.79 billion in 2023, then narrowed to KRW 3.22 billion in 2024 and KRW 2.82 billion in 2025. However, the operating margin moved from -3.4 percent in 2022 to -27.7 percent in 2023, -36.5 percent in 2024, and -43.4 percent in 2025.

Because the sales decline outpaced the reduction in losses, the margin worsened even in 2024 and 2025, when the absolute loss shrank. Press reports attribute the 2025 operating loss to selling, general and administrative expenses exceeding gross profit, with sales commissions the largest SG&A item.

Net results differ depending on the basis. Net loss attributable to controlling shareholders was KRW 13.9 billion in 2022, KRW 149 million in 2023, KRW 5.71 billion in 2024, and KRW 16.8 billion in 2025, a loss for four consecutive years from 2022 to 2025.

Net income including non-controlling interests was a net loss of KRW 13.6 billion in 2022, net income of KRW 142 million in 2023, a net loss of KRW 5.72 billion in 2024, and a net loss of KRW 16.8 billion in 2025, so 2023 was the only profitable year on that basis.

Press reports say the company expensed KRW 10.8 billion of investment costs at the end of 2025, including an impairment on its stake in subsidiary BL Melanics and losses on equity-method investments, and cite these charges as the main reason for the 2025 net loss.

Quarterly results began with Q3 2025 sales of KRW 907 million and an operating loss of KRW 503 million. Q4 2025 sales were KRW 810 million (down 10.6 percent from the prior quarter), with an operating loss of KRW 1.14 billion and a controlling-shareholder net loss of KRW 13.8 billion.

Q1 2026 sales rose to KRW 1.52 billion (up 87.1 percent from the prior quarter) and operating profit was KRW 49.06 million, a swing to profit. Q2 2026 posted an operating loss of KRW 1.34 billion, a return to loss, and a controlling-shareholder net loss of KRW 1.66 billion.

Q3 2026 sales were KRW 1.12 billion (up 23.4 percent year on year), operating profit was KRW 32.45 million, a swing to profit from a year earlier, and the controlling-shareholder net loss narrowed to KRW 207 million from the prior quarter and the prior-year quarter.

The controlling-shareholder net loss for the last four quarters (Q4 2025 to Q3 2026) totaled KRW 15.2 billion; because the gap between operating results and controlling-shareholder results is wide, the composition of non-operating items is the next item to check.

At end-2025 total equity was KRW 7.93 billion (KRW 7.9 billion attributable to controlling shareholders), total liabilities were KRW 10.3 billion, and the debt ratio rose to 129.5 percent from 50.2 percent in 2024.

Operating cash flow was -KRW 11 billion in 2022, KRW 7.99 billion in 2023, -KRW 3.04 billion in 2024, and -KRW 284 million in 2025.

05

Industry analysis

The health functional food market has declined for three consecutive years and shrank 1.4 percent in 2025. Consumption is moving from TV home shopping to digital commerce channels, and falling TV shopping viewership is cited as a factor behind the decline in BL Pharmtech's sales and profitability.

The company attributes its 2025 sales decline to shrinking low-margin health food items and says it is reshaping its portfolio around higher-margin products.

The distribution business accounts for a large share of revenue, yet analysts point to high distribution costs such as sales commissions as a drag on profitability.

In drug development, molecular glue degraders are attracting attention as next-generation technologies that bind to antibodies, antibody-drug conjugates, and targeted therapies to amplify their effects.

In June 2026, at BIO USA 2026, the company said it agreed with several global companies to sign confidentiality agreements and share follow-up data. The company also said a French pharmaceutical company showed interest in developing ML301 as a small-molecule treatment for brain tumors.

In cycle terms, BL Pharmtech is in a period where its legacy health food business is contracting while its drug pipeline is in an early validation phase. Compared with other drug developers in the same biopharma sector, its revenue is mostly generated from health foods, which sets it apart.

In Europe, the company believes the regional advanced biotech support policies and South Korea's accession to Horizon Europe are improving the environment for global cooperation.

06

Outlook

In March 2026 the company said it aimed to post a profit starting that year, and it disclosed a swing to operating profit in Q1 2026 as a sign of improvement. However, the operating loss of KRW 1.34 billion in Q2 2026 means whether the target is met should be checked on an annual basis rather than quarter by quarter.

Semi-annual 2026 results showed sales and operating profit revised down somewhat from Q1, and the company said this reflected stricter accounting standards applied in the external auditor's half-year review.

CEO Park Young-chul said he would continue serving without compensation until the company achieves a full return to profitability and exits the investment warning designation, and presented a two-track strategy of improving earnings while pursuing drug licensing through year-end.

On commerce, the company plans to expand YouTube and TikTok sales through its partnership, with a focus on the United States, Japan, Vietnam, Malaysia and Singapore. The company also said it is pursuing the acquisition of a business that generates stable sales and operating profit.

On the pipeline side, the company attended BIO Europe 2026 from November 9 to 11, 2026, where it discussed licensing prospects for ML301 and the ML303 and ML304 programs.

The company's chief technology officer also noted that combining ML301 with Amgen's bispecific T-cell engager platform could enhance immuno-oncology response.

The next checkpoints are whether a licensing agreement is signed and on what terms, and whether the 2026 annual report shows the operating margin turning positive.

07

Valuation

PER
—
PBR
5.4×
ROE
-101.0%
EPS
-₩543
BPS
₩296
Dividend per share
₩0

PER cannot be calculated because of the controlling-shareholder net loss over the last four quarters. PBR sits in a range that carries a large premium to net asset value, which can be read as the share price reflecting licensing expectations more than the size of equity.

Dividend yield is effectively near zero, so the stock does not offer a meaningful shareholder return through dividends. Press reports say the share price has repeatedly swung sharply on licensing-expectation news, responding more to pipeline headlines than to earnings trends.

Industry observers have said that whether an actual licensing contract is signed will be a watershed for the company's valuation. With total equity at KRW 7.93 billion, PBR can move considerably with changes in the equity base, and continued losses would weigh on how PBR is read.

Valuation interpretation therefore needs to weigh the last four quarters of net results, the size of equity, and whether any licensing deal is signed.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Licensing potential of the molecular glue pipeline

The company said it is pursuing licensing discussions with three to four domestic and overseas companies in parallel, and it sought out licensing for ML301 at BIO USA 2026 in June 2026 and BIO Europe 2026 in November 2026.

According to the company, ML301 showed potential to suppress tumor growth in ALT-positive cancer cells and animal model evaluations. If a deal is signed, it could be a variable that changes a revenue structure currently centered on health foods.

Quarterly swing to profit and narrowing losses

Operating profit was KRW 49.06 million in Q1 2026 and KRW 32.45 million in Q3 2026, both profitable quarters. The controlling-shareholder net loss narrowed from KRW 1.66 billion in Q2 2026 to KRW 207 million in Q3 2026.

The company explains that it exited low-profitability businesses and reshaped its portfolio around higher-margin products.

Expanding commerce channels and distribution ties

In September 2026 the company entered a strategic partnership to sell Gainpad and Dr. Feets through global social media channels including YouTube and TikTok. The company said the partner holds TikTok global distribution rights granted to only six companies in Korea. The plan is to expand sales centered on the United States, Japan, Vietnam, Malaysia and Singapore.

09

Bear factors

Four straight years of operating losses and wider net losses

Operating losses persisted from 2022 through 2025, and the controlling-shareholder net loss widened to KRW 16.8 billion in 2025 from KRW 5.71 billion in 2024.

The company returned to an operating loss of KRW 1.34 billion in Q2 2026, and the controlling-shareholder net loss over the last four quarters totaled KRW 15.2 billion. The operating margin was -43.4 percent in 2025, lower than -3.4 percent in 2022.

Shrinking sales and a contracting health food market

Sales declined from KRW 80.6 billion in 2022 to KRW 6.51 billion in 2025, and the health functional food market has shrunk for three years in a row. Falling TV home shopping viewership and the shift toward digital commerce are weighing on sales. Semi-annual 2026 sales and operating profit were revised down somewhat from Q1.

Balance sheet strain and going-concern uncertainty

The debt ratio rose to 129.5 percent at end-2025 from 50.2 percent in 2024, with total liabilities of KRW 10.3 billion. The external auditor flagged a material uncertainty about the company's ability to continue as a going concern in its 2025 audit report, citing accumulated deficits of KRW 99.6 billion. Operating cash flow remained negative at -KRW 284 million in 2025.

10

Risk factors

Licensing uncertainty

Licensing of the molecular glue platform was the central driver of the share price in 2026, but whether a deal is signed, and its terms and timing, have not been disclosed. ML301 is still at an early stage that has not entered clinical trials, and the company said partners are testing it on antibody platforms. If expectations do not translate into results, share price volatility could widen again.

Volatility from equity investments and affiliates

Press reports say the controlling-shareholder net loss widened in 2025 because of investment cost write-offs and losses on equity-method affiliates. Valuation changes in such investments can move net results independently of operating performance.

The Korea Mine Rehabilitation and Mine Safety Corporation has said it is preparing a lawsuit over a shareholder agreement related to a Mongolian coal mine, arguing its terms are unfair.

Share price volatility and governance

The share price has repeatedly surged and fallen on licensing expectations, and the company has been designated under exchange investment warning and attention categories as well as a short-selling overheating list. Press reports say CEO Park Young-chul raised his stake through open-market purchases.

The company has said the audit opinion itself remains unqualified, even as the auditor flagged going-concern uncertainty.

11

What to watch next

  1. Fiscal year ends December 31, 2026; annual report due by late March 2027

    The 2026 annual report, the next periodic filing, will show whether the annual operating margin, total equity, and the auditor's going-concern paragraph change.

  2. By end of December 2026 (product scheduled for second-half launch)

    Whether the GLP-1 weight management probiotic launches as planned and whether overseas sales through the social commerce channel start to appear will show the effect of the commerce expansion.

  3. After November 2026 (timing undetermined)

    Whether a licensing agreement for the ML301 and other molecular glue assets is signed, and whether its upfront payment and royalty terms are disclosed.

  4. Around late February 2027 (the 2025 fiscal year was disclosed on February 27, 2026)

    Whether 2026 annual sales clear the revenue level referenced in investor discussions, and whether a material change in profit structure is disclosed.

  5. Around May 15, 2027

    Whether operating profit stays positive and whether controlling-shareholder net income turns positive in the Q1 2027 quarterly report.

12

Overall view

BL Pharmtech's disclosed results from 2022 to 2025 can be summarized as sales falling from KRW 80.6 billion to KRW 6.51 billion while operating losses persisted for four consecutive years.

Operating profit in Q1 and Q3 2026 signals a quarterly recovery, but the KRW 1.34 billion operating loss in Q2 2026 and the KRW 15.2 billion controlling-shareholder net loss over the last four quarters mean whether profitability can be sustained will be judged in the next periodic reports.

Positive factors include diversification of health food sales channels, quarterly profits from SG&A efficiency, and expanding global discussions on the molecular glue pipeline.

Negative factors include shrinking sales and a contracting health food market, wider net losses from investment write-downs, the auditor's going-concern uncertainty flag, and a pipeline that has not yet entered the clinic.

A signed licensing agreement could change the financial structure and earnings mix, but its terms and timing have not been disclosed. The equity base of KRW 7.93 billion and the 129.5 percent debt ratio at end-2025 are financial points to check in the next periodic report alongside any capital raise.

The gap between management's targets and disclosed results will become visible in the 2026 annual report and the Q1 2027 quarterly report. This report is provided for information only and does not include any buy or sell opinion.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. comp.wisereport.co.kr
  2. asiae.co.kr
  3. core.asiae.co.kr
  4. view.asiae.co.kr
  5. news.jkn.co.kr
  6. biobookmedia.com
  7. biotimes.co.kr
  8. view.asiae.co.kr
  9. opinionnews.co.kr
  10. dhilbo.co.kr
  11. view.asiae.co.kr
  12. news.nate.com
  13. news.nate.com
  14. view.asiae.co.kr
  15. v.daum.net
  16. stockinfo7.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis